BPC June 20 updates: OPK receives swift FDA Approval + updates for EPZM FATE GBT OPHT RDHL SGMO TBPH VICL

Jun 21, 2016 No Comments by

Updates to the Company Pipeline Database for June 20, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary EPZM 10.96 Tazemetostat Relapsed or refractory B-cell NHL cancer Phase 2 Phase 2 update at the American Society of Hematology (ASH) Meeting on Lymphoma Biology – June 18 2016 FATE 2.00 ProHema Adult […]

Daily News Read more

BPC June 13 updates: KMPH issued CRL. MRNS and RVNC both fail Phase 3 trials + updates for ARGS ARIA FCSC MESO ONCE VICL

Jun 14, 2016 No Comments by

Updates to the Company Pipeline Database for June 13, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ARGS 5.95 AGS-003 ADAPT Trial Metastatic renal cell carcinoma (mRCC) Phase 3 Third interim analysis June 2016. Overall survival analysis due 1H 2017 ARIA 8.20 Iclusig (ponatinib) – OPTIC-2L Cancer – second line […]

Daily News Read more

Pipeline updates from reporting companies – ARIA AVEO BCLI BDSI BLPH BSTC BTX CCXI CERU CYTX DERM FOMX GALE GTXI IMDZ MDGN OCUL OMER PBYI STEM TGTX TKAI VICL VKTX VTAE XENE ZIOP

May 11, 2016 No Comments by

Updates to the Company Pipeline Database for May 10, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ARIA 7.64 AP32788 Cancer – non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 enrolling as of May 2016 ARIA 7.64 Brigatinib – ALTA trial Anaplastic lymphoma kinase positive (ALK+) metastatic non-small cell […]

Daily News Read more

61 pipeline updates for 42 companies from May 7 and 8

May 09, 2015 1 Comment

Latest updates to the Company Pipeline Database for May 7 and 8, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ACHN 9.43 ACH-3422 in combination with ACH-3102 HCV Hepatitis C – treatment durations of 6, 8 and 12 weeks Phase 2 Phase 2 to be initiated 2Q 2015. SVR4 results are expected […]

Read more

MDCO Adcom date set + updates for ACAD ATRA BOTA CMRX GEVA HPTX HSGX ISIS KERX MACK NLNK OTIC PTCT RPTP SAGE SRPT TLOG VICL ZIOP

Feb 28, 2015 No Comments

Latest updates to the Company Pipeline Database for February 26-27, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ACAD 37.97 Pimavanserin Parkinson’s disease psychosis (PDP) Phase 2 NDA filing due 1Q 2015 2/28/2015 ATRA 19.56 PINTA 745 Protein-energy wasting Phase 2 Phase 2 unblinding of data […]

Read more

CCXI topline CCX140 data due Fri + updates for FOLD BLUE KPTI VICL NKTR

Dec 12, 2014 1 Comment

Latest updates to the Company Pipeline Database from December 11 2014. Refer to the FDA Calendar for upcoming catalysts. Ticker Price Drug Indication Stage Link Text Updated BLUE  86.12 LentiGlobin – HGB-206 Sickle disease Phase 1/2 Most likely to have initial data 1H 2015, as per JPM estimate 12/12/2014 CCXI 4.49 CCX140 Diabetic nephropathy Phase […]

Read more

CHMP agendas now online. ONTX fails Ph3 pancreatic trial. NAVB files sNDA + updates for SCMP VICL PBYI

Dec 17, 2013 No Comments

The European Medicines Agency (EMA) announced that they are publishing, for the first time, the agendas of the Committee for Medicinal Products for Human Use (CHMP) meetings. The minutes of each of these meetings held in December will be published once they have been adopted by the relevant Committee at its meeting in January. It will then […]

Read more

CYTR data due Wednesday. AVNR fails Phase 2 PRIME trial. SPPI files Belinostat NDA + VICL NWBO news

Dec 10, 2013 No Comments

CytRx Corporation (NASDAQ: CYTR $2.39) announced that it will issue a news release at 8:00 a.m. Eastern time on Wednesday December 11 2013, announcing top-line results from their Phase 2b trial of aldoxorubicin as a first-line treatment for advanced soft tissue sarcomas (STS). They will host a conference call beginning at 10:30 a.m. EST. Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR $4.29) […]

Read more

Pipeline and news updates for INCY ARRY CLVS VICL BMRN SGYP ACOR GENT ENMD DSCO MACK ARIA

Nov 02, 2013 No Comments

Incyte Corporation(Nasdaq: INCY $40.40) provided a pipeline update noting that Phase 3 data of Jakafi (ruxolitinib) in patients with polycythemia vera (PV), are expected in early 2014, with a potential NDA filing in 1H 2014. Data from their Phase 3 trial measuring disease-related symptoms in patients with PV (RELIEF) are due in mid-2014. In addition, Phase 2 data from […]

Read more

VICL fails Phase 3 trial. BIOD still on track for 3Q data release. ACRX NDA filing due 3Q. MDCO offering + updates for PTCI CCXI DSCI ENTA ESPR

Aug 13, 2013 No Comments

Vical Incorporated (Nasdaq:VICL) announced that their Phase 3 trial of Allovectin, in patients with metastatic melanoma, failed to meet both the primary endpoint of objective response rate at 24 weeks and the secondary endpoint of overall survival. Biodel Inc. (Nasdaq:BIOD) maintained guidance that it expects data from their Phase 2 trial of BIOD-123 in 3Q 2013. Esperion […]

Read more

ETRM submits PMA. VICL initiates Phase 3 TransVax trial.

Jun 26, 2013 No Comments

EnteroMedics Inc. (NASDAQ: ETRM) announced that it has submitted a Premarket Approval (PMA) application to the FDA for approval of the Maestro Rechargeable System’s VBLOC vagal blocking therapy as a treatment for obesity. Vical Incorporated (Nasdaq:VICL) and Astellas Pharma Inc. (TOKYO:4503) announced the initiation of a multinational Phase 3 trial of TransVax in approximately 500 hematopoietic cell transplant (HCT) recipients.

Read more